Evidence map›Paper›PMID 42380068›Full record

ArticleJournal of chemical information and modeling2026

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Maria Gabriella Chiariello, Akash Deep Biswas, Carmen Gratteri, Ingrid Guarnetti Prandi, Siewert-Jan Marrink, Andrea Beccari, Carmine Talarico

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria Gabriella ChiarielloLIGHT S.c.a.r.l., Via Branze 45, Brescia 25123, Italy.ORCID 0000-0003-1076-682X
Akash Deep BiswasDompé Farmaceutici S.p.A. - Exscalate, Via Tommaso de Amicis 95, Napoli 80145, Italy.
Carmen GratteriLIGHT S.c.a.r.l., Via Branze 45, Brescia 25123, Italy.
Ingrid Guarnetti PrandiIndependent Researcher, Largo Martin Luther King, 21, Ciampino 00043, Italy.ORCID 0000-0002-3253-1821
Siewert-Jan MarrinkGroningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Nijenborgh 4, Groningen 9747 AG, The Netherlands.ORCID 0000-0001-8423-5277
Andrea BeccariDompé Farmaceutici S.p.A. - Exscalate, Via Tommaso de Amicis 95, Napoli 80145, Italy.ORCID 0000-0001-6830-2695
Carmine TalaricoDompé Farmaceutici S.p.A. - Exscalate, Via Tommaso de Amicis 95, Napoli 80145, Italy.ORCID 0000-0003-4789-0955

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptor tyrosine kinase KIT is essential for cell proliferation and differentiation, and its aberrant activation contributes to cancers such as acute myeloid leukemia and gastrointestinal stromal tumors. KIT activation normally requires stem cell factor (SCF)-induced dimerization, whereas oncogenic mutations can drive ligand-independent signaling. Here, we employ multiscale molecular dynamics simulations based on the Martini 3 coarse-grained (CG) force field to investigate the dimerization mechanisms of full-length KIT in both wild-type (WT) and oncogenic mutant forms within a realistic membrane environment. For the WT receptor, simulations capture SCF-driven dimerization through a cooperative "zipper-like" mechanism involving sequential domain-domain interactions. In contrast, the T417I, Δ418-419 mutant forms stable dimers spontaneously in the absence of SCF, stabilized by enhanced D5-D5 hydrophobic contacts. Back-mapping and atomistic refinement yielded the first all-atom (AA) structural model of the full-length KIT (T417I, Δ418-419) mutant, consistent with the V-shaped extracellular conformation observed experimentally. This study provides mechanistic insight into KIT activation and establishes a Martini 3-based framework for simulating receptor assembly and guiding the design of antibodies or small molecules that disrupt aberrant dimerization.

Indexed as

Molecular Dynamics SimulationProtein MultimerizationProto-Oncogene Proteins c-kitHumansMutationStem Cell FactorProto-Oncogene Proteins c-kitStem Cell Factor

Identifiers

PMID42380068
PMCPMC13370856

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.